# Study of Tislelizumab Plus Chemotherapy vs Chemotherapy as Perioperative Treatment in Participants With HER2 Negative Breast Cancer

> **NCT04498793** · PHASE2 · UNKNOWN · sponsor: **Cancer Institute and Hospital, Chinese Academy of Medical Sciences** · enrollment: 55 (estimated)

## Conditions studied

- HER2-negative Breast Cancer

## Interventions

- **BIOLOGICAL:** Tislelizumab
- **DRUG:** Nab paclitaxel
- **DRUG:** Doxorubicin
- **DRUG:** Epirubicin
- **DEVICE:** Cyclophosphamide

## Key facts

- **NCT ID:** NCT04498793
- **Lead sponsor:** Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-09
- **Primary completion:** 2021-12
- **Final completion:** 2022-12
- **Target enrollment:** 55 (ESTIMATED)
- **Last updated:** 2020-09-03

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04498793

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04498793, "Study of Tislelizumab Plus Chemotherapy vs Chemotherapy as Perioperative Treatment in Participants With HER2 Negative Breast Cancer". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04498793. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*